Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events of any severity · HIV‐positive and ‐negative adults and children
MVA85A leads to higher adverse events of any severity compared with placebo (high certainty).
1 finding from 1 review
Safety Any serious adverse event · adults with fibromyalgia
It is very uncertain whether mirtazapine changes safety: serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder
Vortioxetine probably leads to higher drop‐out due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts due to adverse events · patients with restless legs syndrome
Summary of findings: levodopa showed no clear difference in dropouts due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission
Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · preventing UTI
Any cranberry product showed no clear difference in gastrointestinal adverse events compared with placebo or control (moderate certainty).
1 finding from 1 review
Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in gastrointestinal adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes gastrointestinal adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review
Safety Any serious adverse event · patients with fibromyalgia
It is very uncertain whether serotonin noradrenaline reuptake inhibitors changes safety (serious adverse events) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events Short‐term · Adults with plantar heel pain¹
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects or other adverse events · patients diagnosed with clinical and laboratory‐confirmed diagnosis of infectious mononucleosis (glandular fever)
1 finding from 1 review
Adverse events: preterm delivery · women undergoing assisted reproduction
Intrauterine infusion/injection of autologous platelet‐rich plasma may leads to higher adverse events: preterm delivery compared with no intervention or placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Treatment‐related adverse events · 13 people with LOPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review
Serious adverse events by week 8 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in serious adverse events by week 8 compared with placebo (low certainty).
1 finding from 1 review